Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06098729
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), Exerscrip LLC (Industry)
24
1
1
10
2.4

Study Details

Study Description

Brief Summary

The challenges of living with type 1 diabetes often stand in the way of getting enough exercise. Continuous blood sugar monitoring has revolutionized type 1 diabetes care but remains underutilized to sustainably support exercise and related behaviors. This research will develop a mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Digital Exercise
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Informatics-Based Digital Intervention to Promote Safe Exercise in Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes - A Feasibility Study
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Digital Exercise

Behavioral: Digital Exercise
A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently

Outcome Measures

Primary Outcome Measures

  1. Feasibility of usage [4 weeks]

    Minutes of using application to exercise. 0 minutes/week is the lowest value, 150 minutes/week meets clinically recommended amounts.

  2. Acceptability [4 weeks]

    Likert-style survey of participant satisfaction. Responses are on a scale from 1 (very dissatisfied) to 5 (very satisfied)

  3. Accuracy [4 weeks]

    Accuracy to predict lapses in exercise behavior ahead of time. 50% accuracy is the lowest possible value (ie, equivalent to random guessing), 80% accuracy is the goal of the study, and 100% accuracy would be the highest possible accuracy.

Secondary Outcome Measures

  1. Motivation states for physical activity [6 weeks]

    Cravings for Rest and Volitional Energy Expenditure (CRAVE) survey of motivation states for physical activity. Scores range from 0 (not at all) to 10 (more than ever).

  2. Moderate to vigorous physical activity [6 weeks]

    Minutes of moderate to vigorous physical activity registered by hip accelerometer. 0 minutes/week is the lowest value, 150 minutes/week meets clinically recommended amounts.

  3. Interview themes [6 weeks]

    Qualitatively-identified determinants and sequalae of motivation states for physical activity

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis with type 1 diabetes (T1D) or other insulin deficiency diabetes (latent autoimmune disease of adulthood, diabetes secondary to pancreatitis)

  • Low exercise levels

  • Smartphone ownership

  • English literacy

  • Under regular care by a healthcare provider

  • Home Broadband wireless Internet or cell phone network (≥25 mbps downloads, ≥3 mbps uploads)

Exclusion Criteria:
  • Diabetic ketoacidosis not clearly related to pump site failure in past 6 months

  • 1 episode of severe hypoglycemia (altered mental and/or physical status requiring assistance from another person for recovery) in past 6 months

  • A1c ≥10.0%

  • Resting blood pressure >145mmHg systolic or >90 mmHg diastolic

  • Myocardial infarction or angina in past 6 months

  • Renal failure

  • Pregnancy

  • Cognitive impairment

  • Severe retinopathy or neuropathy.

  • Other chronic disease or physical disability that would influence exercise intervention

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yale School of Medicine New Haven Connecticut United States 06510

Sponsors and Collaborators

  • Yale University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Exerscrip LLC

Investigators

  • Principal Investigator: Garrett Ash, PhD, Yale School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT06098729
Other Study ID Numbers:
  • 2000035846
  • K01DK129441
First Posted:
Oct 24, 2023
Last Update Posted:
Oct 24, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 24, 2023